Edition:
United States

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

11.23EUR
10:23am EDT
Change (% chg)

€-0.02 (-0.18%)
Prev Close
€11.25
Open
€11.28
Day's High
€11.34
Day's Low
€11.13
Volume
79,797
Avg. Vol
427,667
52-wk High
€15.83
52-wk Low
€8.26

Latest Key Developments (Source: Significant Developments)

Innate Pharma FY operating profit down at 7.6 million euros
Tuesday, 7 Mar 2017 02:55am EST 

Innate Pharma SA : Cash and cash equivalents at December 31, 2016 230.7 million euros ($244.47 million) versus 273.7 million euros year ago . FY net profit of 12.6 million euros versus loss of 6.7 million euros year ago . FY operating profit of 7.6 million euros versus loss of 10.8 million euros year ago .FY revenue 65.7 million euros versus 25.1 million euros year ago.  Full Article

BRIEF-Innate Pharma FY operating result turns to profit of 7.6 million euros
Tuesday, 7 Mar 2017 01:00am EST 

Corrects headline to show that FY 2016 operating result was positive compared to loss in 2015..Innate Pharma SA : Cash and cash equivalents at December 31, 2016 230.7 million euros ($244.47 million) versus 273.7 million euros year ago . FY net profit of 12.6 million euros versus loss of 6.7 million euros year ago . FY operating profit of 7.6 million euros versus loss of 10.8 million euros year ago .FY revenue 65.7 million euros versus 25.1 million euros year ago.  Full Article

Innate Pharma announces top-line results from EffiKIR trial
Monday, 6 Feb 2017 01:00am EST 

Innate Pharma SA : Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab . Study did not meet primary efficacy endpoint . Confirms safety profile of lirilumab as a monotherapy . Broad clinical program ongoing, investigating lirilumab in a variety of tumor indications and combinations . No statistically significant difference between either lirilumab arms and placebo arm on leukemia-free survival (LFS) nor on other efficacy endpoints .Adverse events encountered with lirilumab were consistent with previously reported safety profile of lirilumab.  Full Article

Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb
Monday, 9 Jan 2017 01:00am EST 

Innate Pharma SA : Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb .Per licensing agreement for lirilumab, Bristol-Myers Squibb paid Innate Pharma a $15 million milestone payment for continued exploration of lirilumab in combination with Opdivo(nivolumab).  Full Article

Innate Pharma and Orega Biotech present preclinical data on IPH52
Tuesday, 19 Apr 2016 09:00am EDT 

Innate Pharma SA:Innate Pharma and Orega Biotech presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program.Novel, potent anti-CD39 antibody, IPH52, validated in preclinical models.  Full Article

Innate Pharma presents new preclinical data supporting development of IPH4301
Monday, 18 Apr 2016 09:00am EDT 

Innate Pharma SA:New preclinical data further supporting development of IPH4301 presented at AACR meeting.Presented a new set of preclinical data further validating potential of its first-in-class anti-mica/b antibody IPH4301.  Full Article

Innate Pharma says DSMB meeting recommends continuation of EffiKIR trial
Wednesday, 16 Mar 2016 02:00am EDT 

Innate Pharma SA:Sixth DSMB meeting of the EffiKIR trial recommends continuation without modification.Data on primary endpoint, leukemia-free survival, are expected in second half of 2016.  Full Article

Innate Pharma to start phase I clinical trial of monalizumab
Monday, 8 Feb 2016 01:00am EST 

Innate Pharma SA:Announces the start of phase I clinical trial of monalizumab in combination with durvalumab.‍This fifth trial with monalizumab completes roll-out of initial clinical plan, due to start reading out in 2017​.Trial ‍will include up to 208 patients, and will be performed in United States and in Europe.  Full Article

Innate Pharma enters licensing agreement with OREGA Biotech
Sunday, 10 Jan 2016 04:30pm EST 

Innate Pharma SA:Enters into an exclusive licensing agreement by which OREGA Biotech grants it full worldwide rights to its program of anti-CD39 checkpoint inhibitors.OREGA Biotech will receive undisclosed upfront payment, milestone payments for preclinical, clinical and regulatory achievements as well as royalties on net sales.  Full Article

Innate Pharma opens Phase Ib/II trial of monalizumab
Thursday, 17 Dec 2015 01:01am EST 

Innate Pharma SA:Says fourth clinical trial has been opened with monalizumab‍.Phase Ib/II trial testing monalizumab in combination with cetuximab in patients with relapsed or refractory head and neck cancer.‍Multicentric trial, which will include up to 70 patients, will be performed in Europe and United States.  Full Article

More From Around the Web

BRIEF-Innate Pharma expands Phase I/II trial testing lirilumab with Opdivo

* Announces the expansion of Phase I/II trial evaluating lirilumab in combination with Opdivo Source text for Eikon: Further company coverage: (Gdynia Newsroom)